AIP
MACK

Ameritas Investment Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Ameritas Investment Partners’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-865
Closed -$12.8K – 3303
2024
Q1 		$12.8K Hold
865
– – ﹤0.01% 2750
2023
Q4 		$11.6K Hold
865
– – ﹤0.01% 2801
2023
Q3 		$10.7K Hold
865
– – ﹤0.01% 2821
2023
Q2 		$10.6K Buy
+865
New +$10.8K ﹤0.01% 2894
2018
Q2 		– Sell
-1,338
Closed -$8K – 3156
2018
Q1 		$8K Hold
1,338
– – ﹤0.01% 2804
2017
Q4 		$11K Sell
1,338
-12,057
-90% -$112K ﹤0.01% 2737
2017
Q3 		$14K Buy
13,395
+12,055
+900% +$127K ﹤0.01% 2638
2017
Q2 		$13K Hold
1,340
– – ﹤0.01% 2733
2017
Q1 		$32K Hold
1,340
– – ﹤0.01% 2133
2016
Q4 		$43K Hold
1,340
– – ﹤0.01% 1126
2016
Q3 		$67K Buy
+1,340
New +$55.6K ﹤0.01% 1089

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ameritas Investment Partners's MACK Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 865 shares — an estimated $12.8K sold.

Ameritas Investment Partners first reported a position in MACK in Q3 2016 and held it in 11 quarters. The position peaked at $67K in Q3 2016. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Ameritas Investment Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Ameritas Investment Partners sold 865 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $12.8K.
  • Ameritas Investment Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2016 and held it in 11 quarters.
  • Ameritas Investment Partners's Merrimack Pharmaceuticals, Inc. position peaked at $67K in Q3 2016.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.